Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Oct 15 (Reuters) — Kdventures AB: Portfolio Company Modus Therapeutics Temporarily Pauses Enrollment In Phase 2a Study Of Sevuparin In Chronic Kidney Disease With Anemia Pause Is Not Result Of A Regulatory Decision Pause Follows Reporting Of Susar After Serious Adverse Event In Sevuparin Study Proof-of-concept Readout
KDventures announced October 15, 2026, that 51%-owned Modus Therapeutics temporarily paused Part 2 enrollment in its Phase 2a sevuparin trial. The study targets chronic kidney disease with anemia; the pause followed a serious adverse event in a sevuparin-treated patient. The event was reported as a suspected unexpected
Modus Therapeutics has paused enrollment in a Phase 2A study.